1. Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy.
- Author
-
Apolo, Andrea B., Ostrovnaya, Irina, Halabi, Susan, Iasonos, Alexia, Philips, George K., Rosenberg, Jonathan E., Riches, Jamie, Small, Eric J., Milowsky, Matthew I., and Bajorin, Dean F.
- Subjects
CANCER patients ,METASTASIS ,TRANSITIONAL cell carcinoma ,CANCER invasiveness ,CISPLATIN ,CANCER chemotherapy - Abstract
A prognostic model that predicts overall survival (OS) for metastatic urothelial cancer (MetUC) patients treated with cisplatin-based chemotherapy was developed, validated, and compared with a commonly used Memorial Sloan-Kettering Cancer Center (MSKCC) risk-score model. Data from 7 protocols that enrolled 308 patients with MetUC were pooled. An external multi-institutional dataset was used to validate the model. The primary measurement of predictive discrimination was Harrell’s c-index, computed with 95% confidence interval (CI). The final model included four pretreatment variables to predict OS: visceral metastases, albumin, performance status, and hemoglobin. The Harrell’s c-index was 0.67 for the four-variable model and 0.64 for the MSKCC risk-score model, with a prediction improvement for OS (the U statistic and its standard deviation were used to calculate the two-sided P = .002). In the validation cohort, the c-indices for the four-variable and the MSKCC risk-score models were 0.63 (95% CI = 0.56 to 0.69) and 0.58 (95% CI = 0.52 to 0.65), respectively, with superiority of the four-variable model compared with the MSKCC risk-score model for OS (the U statistic and its standard deviation were used to calculate the two-sided P = .02). [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF